Advertisement
Mayo Clinic Proceedings Home

Central Nervous System Tumors

      Central nervous system tumors are relatively common in the United States, with more than 40,000 cases annually. Although more than half of these tumors are benign, they can cause substantial morbidity. Malignant primary brain tumors are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in adolescents and adults aged 15 to 34 years. Common presenting symptoms include headache, seizures, and altered mental status. Whereas magnetic resonance imaging helps define the anatomic extent of tumor, biopsy is often required to confirm the diagnosis. Treatment depends on the histologic diagnosis. Benign tumors are usually curable with surgical resection or radiation therapy including stereotactic radiation; however, most patients with malignant brain tumors benefit from chemotherapy either at the time of initial diagnosis or at tumor recurrence. Metastases to the brain remain a frequent and morbid complication of solid tumors but are frequently controlled with surgery or radiation therapy. Unfortunately, the mortality rate from malignant brain tumors remains high, despite initial disease control. This article provides an overview of current diagnostic and treatment approaches for patients with primary and metastatic brain tumors.
      CNS (central nervous system), CSF (cerebrospinal fluid), CT (computed tomography), GBM (glioblastoma multiforme), MRI (magnetic resonance imaging), PCV (procarbazine, lomustine, and vincristine), PFS (progression-free survival), SRS (stereotactic radiosurgery), WHO (World Health Organization)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Jemal A
        • Siegal R
        • Ward E
        • Murray T
        • Xu J
        • Thun MJ
        Cancer statistics, 2007.
        CA Cancer J Clin. 2007; 57: 43-66
        • Department of Health and Human Services
        • Centers for Disease Control and Prevention (CDC)
        • National Program of Cancer Registries (NPCR)
        Central Brain Tumor Registry of the United States.
        (Accessed August 21, 2007.)
        • Wrensch M
        • Minn Y
        • Chew T
        • Bondy M
        • Berger MS
        Epidemiology of primary brain tumors: current concepts and review of the literature.
        Neuro Oncol. 2002; 4: 278-299
        • Posner JB
        Neurologic Complications of Cancer. Oxford University Press, Philadelphia, PA1995
        • Souhami L
        • Seiferheld W
        • Brachman D
        • et al.
        Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 39-05 protocol.
        Int J Radiat Oncol Biol Phys. 2004; 60: 853-860
        • Glantz MJ
        • Cole BF
        • Forsyth PA
        • et al.
        Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology.
        Neurology. 2000; 54: 1886-1893
        • Packer RJ
        • Ater J
        • Allen J
        • et al.
        Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.
        J Neurosurg. 1997; 86: 747-754
        • Keles GE
        • Lamborn KR
        • Berger MS
        Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome.
        J Neurosurg. 2001; 95: 735-745
        • van den Bent MJ
        • Afra D
        • de Witte O
        • EORTC Radiotherapy and Brain Tumor Groups, UK Medical Research Council
        • et al.
        Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
        Lancet. 2005; 366: 985-990
        • Klein M
        • Heimans JJ
        • Aaronson NK
        • et al.
        Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study.
        Lancet. 2002; 360: 1361-1368
        • Shaw E
        • Arusell R
        • Scheithauer B
        • et al.
        Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study.
        J Clin Oncol. 2002; 20: 2267-2276
        • Karim AB
        • Maat B
        • Hatlevoll R
        • et al.
        A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.
        Int J Radiat Oncol Biol Phys. 1996; 36: 549-556
        • Shaw EG
        • Berkey BA
        • Coons SW
        • et al.
        Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG).
        J Clin Oncol. 2006; 24 (Abstract 1500.): 63s
        • Buckner JC
        Factors influencing survival in high-grade gliomas.
        Semin Oncol. 2003; 30: 10-14
        • Prados MD
        • Scott C
        • Curan Jr, WJ
        • Nelson DF
        • Leibel S
        • Kramer S
        Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.
        J Clin Oncol. 1999; 17: 3389-3395
        • Stewart LA
        Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomised trials.
        Lancet. 2002; 359: 1011-1018
        • Medical Research Council Brain Tumor Working Party
        Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
        J Clin Oncol. 2001; 19: 509-518
        • Yung WK
        • Prados MD
        • Yaya-Tur R
        • Temodal Brain Tumor Group
        • et al.
        Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse.
        J Clin Oncol. 1999; 17: 2762-2771
        • Smith JS
        • Tachibana I
        • Passe SM
        • et al.
        PTEN Mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.
        J Natl Cancer Inst. 2001; 93: 1246-1256
        • Walker MD
        • Alexander Jr, E
        • Hunt WE
        • et al.
        Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial.
        J Neurosurg. 1978; 49: 333-343
        • Stupp R
        • Mason WP
        • van den Bent MJ
        • European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group
        • et al.
        Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
        N Engl J Med. 2005; 352: 987-996
        • Hegi ME
        • Diserens AC
        • Gorlia T
        • et al.
        MGMT gene silencing and benefit from temozolomide in glioblastoma.
        N Engl J Med. 2005; 352: 997-1003
        • Westphal M
        • Hilt DC
        • Bortey E
        • et al.
        A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
        Neuro Oncol. 2003; 5: 79-88
        • Jenkins RB
        • Blair H
        • Ballman KV
        • et al.
        A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
        Cancer Res. 2006; 66: 9852-9861
        • Hoang-Xuan K
        • Capelle L
        • Kujas M
        • et al.
        Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.
        J Clin Oncol. 2004; 22: 3133-3138
        • Brada M
        • Viviers L
        • Abson C
        • et al.
        Phase II study of primary temozolomide chemotherapy in patients with WHO grade II glioma.
        Ann Oncol. 2003; 14: 1715-1721
        • Buckner JC
        • Gesme Jr, D
        • O'Fallon JR
        • et al.
        Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
        J Clin Oncol. 2003; 21: 251-255
        • Quinn JA
        • Reardon DA
        • Friedman AH
        • et al.
        Phase II trial of temozolomide in patients with progressive low-grade glioma.
        J Clin Oncol. 2003; 21: 646-651
        • Pace A
        • Vidiri A
        • Galiè E
        • et al.
        Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
        Ann Oncol. 2003; 14: 1722-1726
        • Cairncross G
        • Berkey B
        • Shaw E
        • et al.
        Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
        J Clin Oncol. 2006; 24: 2707-2714
        • van den Bent MJ
        • Carpentier AF
        • Brandes AA
        • et al.
        Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
        J Clin Oncol. 2006; 24: 2715-2722
        • Cairncross G
        • Macdonald D
        • Ludwin S
        • National Cancer Institute of Canada Clinical Trials Group
        • et al.
        Chemotherapy for anaplastic oligodendroglioma.
        J Clin Oncol. 1994; 12: 2013-2021
        • van den Bent MJ
        • Taphoorn MJ
        • Brandes AA
        • et al.
        Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
        J Clin Oncol. 2003; 21: 2525-2528
        • Gornet MK
        • Buckner JC
        • Marks RS
        • Scheithauer BW
        • Erickson BJ
        Chemotherapy for advanced CNS ependymoma.
        J Neurooncol. 1999; 45: 61-67
        • Go RS
        • Taylor BV
        • Kimmel DW
        The natural history of asymptomatic meningiomas in Olmsted County, Minnesota.
        Neurology. 1998; 51: 1718-1720
        • Pollock BE
        • Stafford SL
        • Utter A
        • Giannini C
        • Schreiner SA
        Stereotactic radiosurgery provides equivalent tumor control to Simpson Grade 1 resection for patients with small- to medium-size meningiomas.
        Int J Radiat Oncol Biol Phys. 2003; 55: 1000-1005
        • Park P
        • Chandler WF
        • Barkan AL
        • et al.
        The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas.
        Neurosurgery. 2004; 55: 100-106
        • Batchelor T
        • Carson K
        • O'Neill A
        • et al.
        Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07.
        J Clin Oncol. 2003; 21: 1044-1049
        • DeAngelis LM
        • Seiferheld W
        • Schold SC
        • Fisher B
        • Schultz CJ
        Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
        J Clin Oncol. 2002; 20: 4643-4648
        • Doolittle ND
        • Miner ME
        • Hall WA
        • et al.
        Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors.
        Cancer. 2000; 88: 637-647
        • Packer RJ
        • Cogen P
        • Vezina G
        • Rorke LB
        Medulloblastoma: clinical and biologic aspects.
        Neuro Oncol. 1999; 1: 232-250
        • Patchell RA
        • Tibbs PA
        • Walsh JW
        • et al.
        A randomized trial of surgery in the treatment of single metastases to the brain.
        N Engl J Med. 1990; 322: 494-500
        • Patchell RA
        • Tibbs PA
        • Regine WF
        • et al.
        Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial.
        JAMA. 1998; 280: 1485-1489
        • Andrews DW
        • Scott CB
        • Sperduto PW
        • et al.
        Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
        Lancet. 2004; 363: 1665-1672
        • Kondziolka D
        • Patel A
        • Lunsford LD
        • Kassam A
        • Flickinger JC
        Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases.
        Int J Radiat Oncol Biol Phys. 1999; 45: 427-434
        • Muacevic A
        • Wowra B
        • Kreth F-W
        • Tonn J-C
        A randomized trial of surgery and radiotherapy versus radiosurgery alone in the treatment of single metastasis to the brain [abstract].
        German Med Sci. 2006; (Abstract OP256)
        • Bindal AK
        • Bindal RK
        • Hess KR
        • et al.
        Surgery versus radiosurgery in the treatment of brain metastasis.
        J Neurosurg. 1996; 84: 748-754
        • O'Neill BP
        • Iturria NG
        • Link MJ
        • Pollock BE
        • Ballman KV
        • O'Fallon JR
        A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases.
        Int J Radiat Oncol Biol Phys. 2003; 55: 1169-1176
        • Pollock BE
        • Brown PD
        • Foote RL
        • Stafford SL
        • Schomberg PJ
        Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease.
        J Neurooncol. 2003; 61: 73-80
        • Antonadou D
        • Paraskevaidis M
        • Sarris G
        • et al.
        Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases.
        J Clin Oncol. 2002; 20: 3644-3650
        • Mehta MP
        • Rodrigus P
        • Terhaard CH
        • et al.
        Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
        J Clin Oncol. 2003; 21: 2529-2536
        • Suh JH
        • Stea B
        • Nabid A
        • et al.
        Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
        J Clin Oncol. 2006 Jan 1; 24 (Epub 2005 Nov 28.): 106-114